Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival

BMC Nephrology

Volumn 11, Issue 1, 2010, Pages

  Gupta, Ajay ^a,b   Zhuo, Jiaying ^b   Zha, Junli ^b   Reddy, Srinivasa ^c   Olp, Jonathan ^d   Pai, Amy ^e  

^a Rockwell Medical   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICHLORODIHYDROFLUORESCEIN DIACETATE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON DEXTRAN; REACTIVE OXYGEN METABOLITE; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; FERRIC ION; IRON(III) HYDROXIDE SUCROSE COMPLEX; IRON(III)-HYDROXIDE SUCROSE COMPLEX; SUCROSE;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; PERIPHERAL BLOOD MONONUCLEAR CELL; STATISTICAL SIGNIFICANCE; SURVIVAL; CELL CULTURE; CELL SURVIVAL; COMPARATIVE STUDY; CYTOLOGY; METABOLISM; MOLECULAR WEIGHT; OXIDATIVE STRESS;

CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CELLS, CULTURED; FERRIC COMPOUNDS; HUMANS; IRON-DEXTRAN COMPLEX; LYMPHOCYTE SUBSETS; MOLECULAR WEIGHT; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, IGG; SUCROSE;

EID: 77955536989     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-11-16     Document Type: Article

References (21)

1. Aspects of immune dysfunction in end-stage renal disease. S Kato M Chmielewski H Honda R Pecoits-Filho S Matsuo Y Yuzawa A Tranaeus P Stenvinkel B Lindholm, Clin J Am Soc Nephrol 2008 3 1526 1533 10.2215/CJN.00950208 18701615
2. Neutrophil dysfunction and infection in end-stage renal disease. M Chonchol, Semin Dial 2006 19 291 296 16893406
3. Iron overload and immunity. G Porto M DeSousa, Worl J Gastroenterol 2007 13 4707 4715
4. High dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. R Deicher F Ziai G Cohen M Müllner WH Hörl, Kidney Int 2003 64 728 736 10.1046/j.1523-1755.2003.00125.x 12846772
5. Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. D Guo BL Jaber S Lee MC Perianayagam AJ King BJ Pereira VS Balakrishnan, Clin Nephrol 2002 58 134 142 12227686
6. Decreased CD3+CD16+ natural killer-like T-cell percentage and zeta-chain expression accompany chronic inflammation in hemodialysis patients. T Eleftheriadis C Kartsios E Yiannaki G Antoniadi P Kazila K Pliakos V Liakopoulos D Markala, Nephrology 2009 14 471 5 10.1111/j.1440-1797.2008.01041.x 19486472
7. Natural killer cell alterations correlate with loss of renal function and dialysis duration in hemodialysis patients. H Vacher-Coponat C Brunet L Lyonnet E Bonnet A Loundou J Sampol V Moal B Dussol P Brunet Y Berland F Dignat-George P Paul, Nephrol Dial Transplant 2008 1406 14 18029366
8. Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy. JH Liu YL Liu HH Lin YF Yang HL Kuo PW Lin CC Huang, Int J Clin Pract 2009 63 387 93 10.1111/j.1742-1241.2008.01732.x 18410348
9. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. RA Zager, Clin J Am Soc Nephrol 2006 1 Suppl 1 24 31 10.2215/CJN.01410406 17699373
10. Comparison of oxidative stress markers in hemodialysis patients following administration of iron dextran, sodium ferric gluconate and iron sucrose. AB Pai A Harford AV Boyd C McQuade JP Norenberg P Zager, Pharmacotherapy 2007 27 343 350 10.1592/phco.27.3.343 17316146
11. Uptake and intracellular handling of iron from transferrin and iron chelates by mitogen stimulated mouse lymphocytes. A Djeha JH Brock, Biochem Biophys Acta 1992 1133 147 52 10.1016/0167-4889(92)90062-G 1731957
12. Iron exerts a specific inhibitory effect on CD2 expression of human PBL. GS Carvalho M deSousa, Immunol Lett 1988 19 163 167 10.1016/0165-2478(88)90137-X 2906908
13. Vascular access-related infections: definitions, incidence rates and risk factors. JP LaFrance E Rahme J Lelorier S Iqbal, Am J Kidney Dis 2008 52 982 983 10.1053/j.ajkd.2008.06.014 18760516
14. Two different modalities of iron gluconate iv administration: effects on iron, oxidative and inflammatory status in peritoneal dialysis patients. AF De Vecchi C Novembrino S Lonati S Ippolito F Bamonti, 2007 22 1709 1713 17298995
15. Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apopotosis. M Tenopoulou PT Doulias A Barbouti U Brunk D Galaris, Biochem J 2005 387 703 710 10.1042/BJ20041650 15579135
16. Parenteral iron nephrotoxicity: potential mechanisms and consequences. RA Zager AC Johnson SY Hanson, Kidney Int 2004 66 144 156 10.1111/j.1523-1755. 2004.00716.x 15200421
17. High susceptibility of activated lymphocytes to oxidative stress-induced cell death. GR Degasperi RF Castilho AE Vercesi, An Acad Bras Cienc 2008 80 137 48 18345382
18. Dialyzer membrane type and reuse practice influence polymorphonuclear leukocyte function in hemodialysis patients. M Rao D Guo BL Jaber S Sundaram M Cendoroglo AJ King BJ Pereira VS Balakrishnan HEMO Study Group, Kidney Int 2004 65 682 91 10.1111/j.1523-1755.2004.00429.x 14717942
19. Non-transferrin Bound Iron (NTBI), Cytokine Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD) Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). AB Pai D Raj C McQuade J Olp PP Hicks TA Conner, J Am Soc Nephrol 2008 19 263A
20. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. PS Lim YH Wei YL Yu B Kho, Nephrol Dial Transplant 1999 14 11 2680 7 10.1093/ndt/14.11.2680 10534512
21. Haemodialysis-induced transient CD16+ monocytopenia and cardiovascular outcome. K Rogacev M Ziegelin C Ulrich S Seiler M Girndt D Fliser GH Heine, Nephrol Dial Transplant 2009 24 3480 3486 10.1093/ndt/gfp287 19586969